Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Molecular residual disease interception in locoregionally advanced HPV-positive and HPV-negative HNSCC

Phase 2 trial whose registry primary outcome is ctDNA clearance with AZD2936 compared with observation in locoregionally advanced head and neck squamous cell carcinoma that remains MRD-positive after definitive treatment. ClinicalTrials.gov lists the study as recruiting.

University Health Network, Toronto